Colorectal cancer therapeutics regulatory update

The U.K.'s National Institute for Clinical Excellence (NICE) issued guidance on the use of three advanced colorectal cancer treatments recommending only selective uses for all of them. The Institute recommended that Eloxatin oxaliplatin from Sanofi-Synthelabo be used as a first line combination treatment with 5-fluorouracil and folinic acid (5FU/FA) only in patients whose cancer has spread to the liver. NICE said it did not recommend routine first-line use of Eloxatin because it found no statistically significant evidence that the treatment increases survival rates. ...